Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002814616 | SCV003198402 | uncertain significance | Bloom syndrome | 2022-05-12 | criteria provided, single submitter | clinical testing | This variant has not been reported in the literature in individuals affected with BLM-related conditions. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces phenylalanine, which is neutral and non-polar, with isoleucine, which is neutral and non-polar, at codon 71 of the BLM protein (p.Phe71Ile). |
Ambry Genetics | RCV004064867 | SCV005022250 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-10-28 | criteria provided, single submitter | clinical testing | The p.F71I variant (also known as c.211T>A), located in coding exon 2 of the BLM gene, results from a T to A substitution at nucleotide position 211. The phenylalanine at codon 71 is replaced by isoleucine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |